Share on LinkedInShare on LinkedIn

ARTICLE · 11 MAY 2023

Market Intelligence Thought Leadership Award Winner

Preliminary Injunction Refusal In Generic Drug Patent Infringement Case Overturned

William Fry LLP
William Fry LLP
Contributor
William Fry LLP

William Fry LLP

William Fry advises leading Irish and international companies, covering both the public and private...

View firm profile
Explore more from William Fry LLP

The Court of Appeal has ruled in favour of Biogen, overturning the High Court's decision to refuse preliminary injunctive relief to restrain Neuraxpharm from infringing Biogen's patent.

IrelandIntellectual Property

The Court of Appeal has ruled in favour of Biogen, overturning the High Court's decision to refuse preliminary injunctive relief to restrain Neuraxpharm from infringing Biogen's patent.

The Court of Appeal held the High Court erred in principle in having regard to the fact that Biogen had an unlawful monopoly based on a parent patent (which was ultimately declared invalid) and, more particularly, that it was a decisive factor against the granting of an injunction.

High Court Decision

In its decision of 26 October 2022 (discussed here), the High Court discharged the interlocutory injunction secured by Biogen on 2 August 2022, which prevented the launch of a generic form of Biogen's multiple sclerosis drug, Tecfidera, until the trial of the main action between the parties.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from